Navigation Links
IRSF announces translational research award funding to test potential therapeutics for Rett syndrome
Date:1/27/2010

(Cincinnati, OH) - Today, the International Rett Syndrome Foundation (IRSF) announced that it will commit $446,000 in 2010 to fund a large translational research program to test potential therapeutics for Rett Syndrome in mouse models of the disease. The funds will be awarded through the IRSF's new Advanced Neurotherapeutic Grant of Excellence (ANGEL) mechanism which seeks to provide funds for translational research. IRSF is the world's largest private source of Rett syndrome research funding, supporting nearly $21 million in research programs to date. This is the first ANGEL Grant supported by IRSF in 2010.

The program will be carried out by a team of researchers at Case Western Reserve University School of Medicine, led by David M. Katz, Ph.D., Professor of Neurosciences. Building on previous proof-of-concept studies conducted in Dr. Katz's laboratory, the new program will evaluate existing drugs, as well as molecules under development, which may improve breathing problems one of the more serious complications of the disease as well as other aspects of Rett syndrome. The researchers will systematically assess several classes of compounds, with a particular focus on improving neuronal signaling mediated by Brain Derived Neurotrophic Factor (BDNF), a key molecule implicated in Rett syndrome.

Dr. David Katz, principal investigator on the study commented "These kinds of translational studies are only possible because of a tremendous amount of basic science research, conducted in many different laboratories, which help us identify potential therapeutic targets. We are deeply grateful to IRSF for their support and encouragement."

IRSF Chief Scientific Officer Dr. Antony Horton stated "This study represents a new opportunity to develop potential treatments for Rett syndrome and demonstrates our continued commitment towards advancing new therapeutic strategies to treat and ultimately reverse this devastating disease."

Part of the study will examine drugs that are currently in development for other neurological disorders including Alzheimer's and Huntington's disease which will be provided by Dr. Frank Longo Professor of Neurology and Neurological Sciences at Stanford University. Dr. Longo founded the biotechnology company PharmatrophiX to further develop and commercialize these drugs. Said Dr. Longo "Studies by Dr. Katz and others indicate that compromised BDNF expression might contribute to Rett syndrome. We have developed the first small molecules that mimic a specific domain of the BDNF protein and activate the BDNF receptor; TrkB. Dr. Katz's studies provide an exciting opportunity to determine the therapeutic potential of these molecules for Rett syndrome."


'/>"/>

Contact: Kathryn Kissam
804-519-6231
International Rett Syndrome Foundation
Source:Eurekalert

Related biology news :

1. The Genetics Society of America announces DeLill Nasser Travel Award recipients
2. Emerald BioStructures announces discovery of small molecule modulators of PDE4
3. Pacific Biometrics, Inc. Announces the Appointment of Michael Murphy, PhD as Chief Operating Officer
4. Chiltern Announces Collaboration With Dr Nawab Qizilbash
5. JDRF announces diabetes research program with Johnson & Johnson
6. Biophysical Society announces winners of 2010 Student Travel Awards
7. Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners
8. The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams
9. MODA Announces Availability of Third Generation Mobile Data Acquisition Platform
10. ESHRE announces its campus workshop: Artificial Insemination: An Update
11. Lupus Research Institute announces 2009 novel research grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... (NASDAQ: NBIX ) today announced its financial results for the ... --> --> For the fourth quarter of 2015, ... loss per share, compared to a net loss of $19.4 million, ... For the year ended December 31, 2015, the Company reported a ... compared to a net loss of $60.5 million, or $0.81 loss ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... new stem cell treatment clinic in Quito, Ecuador. The new facility will provide ... applications to patients from around the world. , The new GSCG clinic ...
Breaking Biology Technology: